Enzyme prodrug therapy has the potential to remedy the lack of selectivity associated with the systemic administration of chemotherapy. However, most current systems are immunogenic and constrained to a monotherapeutic approach. We developed a new class of fusion proteins centered about the human enzyme β-glucuronidase (βG), capable of converting several innocuous prodrugs into chemotherapeutics. We targeted βG to phosphatidylserine on tumor cells, tumor vasculature and metastases via annexin A1/A5. Phosphatidylserine shows promise as a universal marker for solid tumors and allows for tumor type-independent targeting. To create fusion proteins, human annexin A1/A5 was genetically fused to the activity-enhancing 16a3 mutant of human βG, expressed in chemically defined, fed-batch suspension culture, and chromatographically purified. All fusion constructs achieved >95% purity with yields up to 740 μg/l. Fusion proteins displayed cancer selective cell-surface binding with cell line-dependent binding stability. One fusion protein in combination with the prodrug SN-38 glucuronide was as effective as the drug SN-38 on Panc-1 pancreatic cancer cells and HAAE-1 endothelial cells, and demonstrated efficacy against MCF-7 breast cancer cells. βG fusion proteins effectively enable localized combination therapy that can be tailored to each patient via prodrug selection, with promising clinical potential based on their near fully human design.
Introduction
It remains difficult to exploit the full potential of chemotherapeutics due to the manifestation of dose-limiting side effects during treatment, which stem from a lack of specificity toward neoplastic disease. Enzyme prodrug therapy (EPT) has the potential to increase the potency of chemotherapeutics, while mitigating the side effects associated with systemic administration, by generating localized, high-dose therapy within solid tumors (Begent et al., 2010) . However, many EPT systems are highly immunogenic, create relatively small therapeutic windows and are limited to a single-target approach by a lack of prodrug variety.
The ability to hit multiple targets is an increasingly important strategy in contrast to the highly selective, single-target approach of the magic-bullet era (Frantz, 2005) . The enzyme β-glucuronidase (βG) presents a promising avenue for EPT, as cell-surface tethered βG can effect a multi-target approach through its capability to simultaneously activate topoisomerase inhibitors, alkylating agents, histone deacetylase inhibitors and anthracyclines. Moreover, additional prodrugs for βG are currently being developed, facilitating further target expansion (Tranoy-Opalinski et al., 2014) .
βG is a tetrameric, lysosomal enzyme that catalyzes the hydrolysis of β-D glucuronic acid residues (Jain et al., 1996; Hassan et al., 2013) . Since βG prodrugs contain hydrophilic glucuronic acid moieties, they do not readily diffuse across cell membranes, greatly reducing prodrug systemic toxicities with respect to their drug equivalents. Further, the sequestration of βG within lysosomes allows for the use of nearly human βG in EPT, with little risk of prodrug conversion by endogenous βG or immunogenicity, a significant concern for the non-human enzymes commonly utilized in EPT (Andrady et al., 2011) . The known 16a3 mutant form of βG contains six point mutations that confer increased activity to βG in less-acidic environments, and, thus, further enhances βG suitability for EPT (Chen et al., 2012) .
Substantial effort has been directed toward localizing suitable EPT enzymes to tumor cells, βG or otherwise, but many approaches suffer distribution limitations or are currently unsafe for clinical use (Xu and McLeod, 2001; Beckman et al., 2007) . In an effort to combat these limitations, we target βG to surface-exposed phosphatidylserine. Phosphatidylserine is an anionic plasma membrane phospholipid asymmetrically found exclusively on the inner membrane leaflet under nonpathological conditions. However, malignant cells and their metastases, the tumor vasculature and cultured tumor cells all explicitly and significantly externalize phosphatidylserine. Phosphatidylserine expression results from a loss of lipid asymmetry that occurs without cell damage or external activators present, making outer leaflet phosphatidylserine a promising malignant cell fingerprint (Riedl et al., 2011) . Further, the feasibility of phosphatidylserine targeting has been validated by the clinical success of Bavituximab, a phosphatidylserine binding antibody (Tabagari et al., 2009) .
To target phosphatidylserine, we utilize the proteins annexin A1 and A5, both of which strongly and specifically bind to phosphatidylserine. We have previously demonstrated a strong specificity of annexin targeting to cancer tissue compared with normal tissue in vivo, by showing that an A5-directed fusion protein localizes entirely to the tumor site and significantly slows tumor growth without noticeable side effects (Van Rite et al., 2013) . We have also shown that annexin A5-directed fusion proteins will not bind to confluent endothelial cells, which simulate healthy vasculature Krais et al., 2013) . These data, combined with the success of Bavituximab, lend proof toward the applicability and safety of annexin-directed therapeutics.
Here, we utilize both annexin A1 and A5. Annexin A5 displays stronger binding to phosphatidylserine than A1, but has been shown to trimerize upon binding, subsequently causing endocytosis. In contrast, A1 binds in a monomeric fashion, forming a halo-like effect around the cell (Janshoff et al., 2001; Kenis et al., 2004) . This distinction may be important for annexin-directed EPT systems, especially those that require the external presence of the enzyme, such as βG, as any fusion protein internalization would likely be directly linked to decreases in system performance. It remains unclear whether A5 internalization still occurs in A5 fusion proteins, since fusion creates significant steric hindrance to trimerization. Thus, both A1 and A5 in fusion merit investigation.
Phosphatidylserine targeting adds another layer to the multieffect approach as it enables cell-surface tethering of βG to both tumor cells and the tumor vasculature, without displaying preference toward either. Due to diffusion limitations, tumor volumes cannot surpass 1-2 mm 3 without the support of vasculature for nutrients and oxygen (Folkman, 1990) ; therefore, the tumor vasculature is an excellent target for annexin-directed EPT. Moreover, tumor vascular targeting is especially attractive since endothelial cells pose an easily accessible target, are more genetically stable than malignant cells, and damage to endothelial cells amplifies downstream (Liu and Deisseroth, 2006) . Annexin-βG fusion proteins enact EPT via a two-step administration scheme (Fig. 1) . First, the fusion protein is delivered to the tumor via the bloodstream, bypassing healthy tissue, but binding to tumor vasculature endothelial cells and directly to tumor cells via uptake through gaps in leaky tumor vasculature (enhanced permeability and retention effect). After unbound fusion proteins are Fig. 1 Overview of how annexin-βG fusion proteins enact EPT. Annexin-βG fusion proteins (βG core each with four annexins) are systemically administered and bind to phosphatidylserine (PS, gray filled circle) encountered on tumor cells and tumor endothelial cells. While PS is present in healthy vasculature and tissue, cells restrict PS to the cytoplasmic leaflet and PS is thus not extracellularly exposed as a target. Once any residual fusion protein has been cleared from circulation, a prodrug ( + ), containing a hydrophilic glucuronide ( ), is systemically administered but does not readily diffuse across the cell membrane, thus remaining relatively innocuous. Prodrug glucuronides ( ) are cleaved upon interaction with bound βG directly within the tumor environment and endothelial cell bound βG in the tumor vasculature. Drugs generated ( ) within the vasculature are largely carried into the tumor environment via convection through the leaky gaps. Once cleaved, drugs ( ) are free to diffuse across cell membranes and enact their cytotoxic effects, as well as diffuse into cells without bound fusion protein (bystander effect).
allowed to clear, the prodrug is administered systemically and converted to its drug equivalent upon interaction with surface tethered βG at and within the tumor site. Drugs generated at the exterior surface of endothelial cells in the tumor vasculature are carried by diffusion and convection into the tissue, as the pressure inside the blood vessel is high compared with the surrounding tissue. Now in the tumor environment and free to diffuse across cell membranes due their acquired hydrophobicity, the drugs generated create both direct and bystander effects.
Producing βG for translational work remains a challenge, with respect to both quantity and quality. Human βG requires a mammalian production system to provide the post-translational modifications necessary to confer activity to βG, as without glycosylation βG remains inactive (Shipley et al., 1993) . Especially for βG in fusion constructs, yields are generally very low, not reported, or the product is simply not purified (Biela et al., 2003; Boado and Pardridge, 2010) . The best reported yield to date for βG in fusion is 3-5 mg/l (Wu et al., 2004) . However, bovine serum was utilized during production, hampering clinical translational potential due to the risk of adventitious agent transfer, such as prions and bovine viruses (Wurm, 2004) . Further, the scalability of this method was impeded by the adherent nature of the cells utilized. Scalability and chemical definition of the production environment thus emerge as two important aspects of βG fusion protein production that require further development to make future clinical translation realizable.
The overall aims of this study were to (i) develop a chemically defined production method using suspension culture for βG fusion proteins; (ii) produce two novel annexin-16a3 mutant βG fusion proteins in pure form; (iii) validate the annexin-βG fusion proteins via binding ability and cytotoxicity toward human pancreatic and breast cancer cells along with human endothelial cells grown to mimic the tumor vasculature. The prodrug utilized for validation was the glucuronide of SN-38 (SN-38G), a topoisomerase I inhibitor. SN-38 has shown efficacy in a PEGylated form against triplenegative, previously-treated breast cancer in a Phase II clinical trial (Osborne et al., 2012) and promise for pancreatic cancer based on outcomes of FOLFIRINOX regimen trials (Conroy et al., 2013) . All aims were achieved in this study: A chemically defined, suspension culture-based production method for βG fusion proteins was developed. Sufficient purified protein yields were achieved to perform in vitro binding and cytotoxicity experiments as proof of concept. The in vitro tests established that both A1 and A5 βG fusion proteins display strong binding and cytotoxicity toward human pancreatic and breast cancer cells and strong binding and moderate cytotoxicity toward human vasculature cells grown to mimic the tumor vasculature.
Materials and Methods

Cell culture
Adherent CHO Flp-In cells were obtained from Life Technologies (Grand Island, NY, USA) and were maintained in Ham's F-12 with 2 mM L-glutamine supplemented with 100 μg/ml Zeocin TM to maintain the Flp-In genotype prior to transfection, replaced with 600 μg/ ml hygromycin B post-transfection, all from Life Technologies. Once adapted to suspension culture, transfected CHO Flp-In cells were maintained in SFM4CHO medium with L-glutamine from GE Healthcare Bio-Sciences (Pittsburgh, PA, USA), supplemented with 1:300 anti-clumping agent (Life Technologies) and sodium hypoxanthine and thymidine (Corning Life Sciences, Tewksbury, MA, USA), at 37°C, 5% CO 2 , and 110 r.p.m. No antibiotic selective pressure was applied to CHO suspension cultures as this suppressed protein yield; however, protein production was maintained at ≥16 passages post adaptation. MCF-7 breast adenocarcinoma and Panc-1 pancreatic epithelioid carcinoma were obtained from ATCC (Manassas, VA, USA) and maintained in Eagle's minimum essential medium with 0.01 mg/ml recombinant human insulin (Life Technologies), or in Dulbecco's Modified Eagles Medium, respectively, all from ATCC. Human abdominal aorta endothelial cells (HAAE-1) were obtained from the Coriell Cell Repositories (Camden, NJ, USA) and cultured on 0.1% w/v gelatin in F-12 K medium (ATCC) with 0.03 mg/ml endothelial cell growth supplement (Corning) and 0.1 mg/ml heparin. All adherent cell culture medium contained 10% fetal bovine serum and penicillin (100 U/ml)/streptomycin (100 mg/ml), both from Atlanta Biologics (Flowery Branch, GA, USA). Cells were cultured at 37°C and 5% CO 2 , not beyond the tenth passage, or the sixth for HAAE cells.
Genetic construction
To create fusion genes, the human clone A5 (Accession: NM_001154), a generous gift from Dr Stuart Lind at the University of Colorado, A1 (BC035993) and a custom synthesized 16a3 mutant βG (mβG) (Chen et al., 2012) were amplified via polymerase chain reaction with the Phusion High Fidelity PCR kit from New England Biolabs (NEB, Ipswich, MA, USA) utilizing tailed primers synthesized by Integrated DNA Technologies (San Jose, CA, USA). The A1 and mβG genes were synthesized by Life Technologies. The 16a3 mutant βG sequence ( Fig. S1 ) and primer sequences with thermal cycles (Fig. S2 ) are given in Supplementary Material. The mutations in βG were as follows: N484Y, S503R, S506G, H513D, Q538L, and S539T. Resulting amplicons contained a His 6 purification tag/HRV 3C cleavage site on the A1/A5 N-terminal and EciI digestion sites on the C-terminal of A1/A5 and the N-terminal of βG. The native βG signal sequence was removed, but the C-terminal propeptide was maintained intact to promote enzyme catalytic activity (Islam et al., 1993) . Amplicons were EciI digested and fused with T4 ligase, both from NEB, according to manufacturer's protocols. Fusions were gel extracted before ligation into the pSecTag/FRT/V5/ HIS/TOPO TA vector (Life Technologies) via the large-insert protocol with a 20-μl volume. Sequence verified plasmids were then cotransfected with pOG44 (1:9 w/w) into Cho Flp-In cells with Lipofectamine 3000, both from Life Technologies, and true transfectants were selected via hygromycin B for >3 weeks.
Fusion protein production and purification
Adherent stable CHO cells lines were adapted sequentially to chemically defined, serum-free suspension culture. Fusion proteins were then produced in 2-week fed-batch cultures in 1-2 liter volumes, split between 500 ml Erlenmeyer flasks (200 ml/flask). Cells were seeded at 3 × 10 5 cells/ml and were fed with 0.7% Cell Boost 2 (GE Healthcare Bio-Sciences) on Day 4 and 0.35% on Day 7 (Han et al., 2011). Fusion proteins were extracted from cell-free culture supernatants via immobilized metal affinity chromatography (IMAC) on two HisTrap Excel columns in series following the GE Healthcare Bio-Sciences protocol, with 0 mM imidazole in the wash buffer and 100 mM in the elution buffer. The collected elutant peak was titrated to 0.9 M ammonium sulfate (Sigma-Aldrich, St. Louis, MO, USA) and then was further purified via hydrophobic interaction chromatography (HIC) on a HiTrap butyl sepharose HP column.
Fusion protein containing fractions from HIC were pooled and concentrated using an Amicon Ultra-15 centrifugal filter (50 kDa cutoff; EMD Millipore, Billerica, MA, USA) prior to gel filtration chromatography (GFC) on a Superdex Increase S200 10/300 GL column; GFC flow rate was set to 0.2 ml/min for high-resolution separation and eluted into Tris-buffered saline (TBS, 20 mM Tris, 150 mM NaCl, pH 8.0). The oligomeric state was determined by comparison of the elution volume containing A1/A5-βG to the elution volume of standard proteins. GFC fractions containing pure fusion proteins, as determined by reducing SDS-PAGE with Imperial stain (Thermo Scientific, Waltham, MA, USA), were pooled, quantitated via Bradford assay (Bio-Rad, Hercules, CA, USA), flash frozen in LN 2 , and stored at −80°C. All columns were obtained from GE Healthcare Bio-Sciences. HIC and GFC were performed on an ÄKTA Pure M1 system (GE Healthcare Bio-Sciences).
Western dot blot
Pure fusion protein (1 μg) was blotted onto a nitrocellulose membrane and dried for 4 h. The membrane was blocked overnight with 1% bovine serum albumin (BSA) in TBS with 0.05% Tween-20, at 4°C with gentle agitation. Blots were stained with 1:200 dilutions of βG (sc-25827), A1 (sc-11387) or A5 (sc-8300) rabbit polyclonal antibodies for 2 h at room temperature. Blots were then washed and incubated with either goat anti-rabbit IgG-HRP (sc-2004) at a 1:5000 dilution or HisDetector Nickel-HRP conjugate (1:50), obtained from KPL (Gaithersburg, MD, USA). Blots were washed, developed with 3,3',5,5'-tetramethylbenzidine (TMB) solution, and imaged on a Bio-Rad ChemiDoc MP CCD imaging system with a chemiluminescent filter. All antibodies were obtained from Santa Cruz Biotechnology (Dallas, TX, USA).
Activity assay
βG enzymatic activity was measured via the fluorescence of the product 4-methylumbelliferone (4-MU) created through βG conversion of the substrate 4-methylumbelliferyl β-D-glucuronide (4-MUG) from Life Technologies. Varying concentrations of 4-MUG were reacted with 0.5 μg of fusion protein in reaction buffer (50 mM bistris, 50 mM triethanolamine, 100 mM acetic acid and 100 ng/ml BSA) at a pH of either 4.5 or 7.4. 4-MU fluorescence was monitored continuously on a microtiter plate reader at 360/460 nm over 1 h and quantitated by comparison with 4-MU standards (SigmaAldrich). Linear range data were analyzed via Michaelis-Menten kinetics with Prism 6 software (GraphPad, La Jolla, CA, USA).
Surface binding visualization
A5-mβG was biotin labeled via a 2-h reaction with SureLINK Biotin from KPL (Gaithersburg, MD, USA). For visualization, MCF-7 cells were plated at 150 k cells/coverslip (20 mm × 20 mm), allowed to adhere overnight, and then fixed with glutaraldehyde to preserve cell morphology. Biotin-labeled A5-mβG (100 mM) was allowed to bind for 2 h. Cells were then thoroughly washed, followed by staining with cell-impenetrable Streptavidin-Alexa-488 at 4 μg/ml to visualize cell-surface bound protein, Cell Mask Deep Red at 2 μg/ml to indicate the cell membrane and Hoechst 33258 at 10 μg/ml to mark nucleic acids. All fluorophores were acquired from Life Technologies. Fluorescence was preserved in fluoro-gel and confocal images acquired immediately following preparation on a Lecia-SP8 confocal laser-scanning microscope (Buffalo Grove, IL, USA), at ×63 in glycerol in both XY and YZ planes.
Dissociation constants and binding stability
O-phenylenediamine color development was utilized to quantitate streptavidin-horseradish peroxidase binding to biotin-labeled fusion proteins bound to the cell surface in the presence and absence of Ca 2+ to determine total and non-specific binding, respectively, as reported previously (Guillen et al., 2014) . The Ca 2+ concentration was set at 2 mM, to mimic serum calcium concentrations of 8.5-10.5 mg/dl (Ganong, 1977) , or 2.12-2.62 mM. A similar assay was applied over 3 days to determine binding stability on live cells. Cells were seeded at 10-20 k/well in 96-well plates, allowed to adhere, treated with 100 nM fusion protein on Day 0 (except controls without protein), thoroughly washed, and then incubated with the appropriate growth medium containing 2 mM Ca 2+ until measurement day. Each day, data minus control, to account for non-specific binding, was compared with Day 0. 
Simulated EPT
Statistical analysis
All data was collected in triplicate and analyzed with Prism 6 software. A two-way ANOVA was utilized with Sidak's post hoc comparisons matched by day for binding stability and Dunnett's post hoc comparisons, matched by day, for simulated EPT.
Results
Pure fusion proteins produced in scalable cultures
Genes were fused to form the constructs A1-mβG and A5-mβG (with 'm' notating the 16a3 mutation), which were then ligated into the pSecTag vector ( Fig. 2A) . Maximum yields obtained from stable CHO Flp-In producer cell lines grown in serum-free, fedbatch suspension cultures were 740 μg/l for both A1-mβG and A5-mβG. Spatial separation of βG from annexin was achieved via a flexible (SG 4 ) 2 linker, carrying no known immunogenicity risk (Gu and Ghayur, 2012) . The separation created by this linker allows (i) both proteins to retain their individual functionalities and (ii) the quaternary structure of fusion proteins to be driven by the strong tetrameric preference of βG. GFC confirmed that both A1-mβG and A5-mβG consistently formed tetramers, as both proteins routinely eluted at a volume (~10 ml) indicative of their predicted tetrameric molecular weights, 460.8 and 449.7 kDa, respectively (Fig. S3, Supplementary Material) . No formation of higher oligomeric states was observed. Therefore, self-assembly of the annexin-βG fusion proteins resulted in a tetrameric βG enzyme core with protruding annexin targeting proteins flexibly tethered to the core, as modeled in Fig. 2B with PyMol 1.2 (Schrödinger, 2010) . Reducing SDS-PAGE (Fig. 2C ) indicated that >95% purity was achieved for both fusion proteins, as determined by densitometry analysis in ImageJ64 (Schneider et al., 2012) . Fusion proteins migrated above their predicted monomeric molecular weights, which is standard for βG fusions and indicative of the heavy glycosylation on βG (Shipley et al., 1993) and the single N-linked biantennary glycosylation site found on A1 (Goulet et al., 1992) . In contrast, A5 is not glycosylated. As this is the first report of A1 produced in mammalian cells, the higher apparent molecular weight of A1-mβG compared with A5-mβG likely indicates that glycosylation of A1 did occur. Identity of purified constructs was confirmed via dot blot (Fig. 2D ). The His 6 tag shown in Fig. 2D was essential for protein purification and construct validation but is easily cleaved with HRV 3C protease due to its location on the N-terminus of annexin and should be removed prior to in vivo experiments to reduce the risk of immunogenicity ( Krais et al., 2013) .
16a3 mutation is effective in fusion constructs
Since βG is a lysosomal enzyme and is thus almost exclusively active in an acidic environment, point mutations around the active site are necessary to increase βG activity at a physiological pH in order to be effective in a therapeutic setting. To determine whether the 16a3 mutation provided enhanced βG activity in fusion constructs, enzyme activity was measured with 4-MUG as the substrate at pH 4.5 and 7.4. Resulting kinetic constants are presented in Table I . The 16a3 mutant βG enzyme in A5-mβG retained 28.3% of its specific activity at pH 7.4 compared with pH 4.5. A1-mβG retained 7.8% specific activity. Both constructs retained activity well above the 1-2% retention previously established for wild-type βG (Chen et al., 2008 (Chen et al., , 2012 . Data in Table I shown as mean ± standard error (SE) (n = 3) and full data sets utilized for kinetic constant determination are presented in Fig. S4 (Supplementary Material) .
Annexin-directed binding is cell-surface localized, strong and stable Utilizing confocal microscopy, we visualized A5-mβG binding to phosphatidylserine on the MCF-7 cell surface in both XY and YZ planes, shown in Fig. 3A-D and E-H, respectively. As shown, bound A5-mβG presence (green) tracked excellently with the cell membrane (red), indicating a cell surface-based interaction is occurring.
To quantitate binding, we measured total and non-specific cell-surface binding over a range of fusion protein concentrations. Total binding was determined in phosphate-buffered saline (PBS) with calcium, necessary for annexin to phosphatidylserine binding. Non-specific binding was determined in PBS without calcium, with EDTA added to chelate any residual calcium. Specific binding was determined by subtraction, as shown in Fig. 4A for A1-mβG binding to phosphatidylserine on the Panc-1 cell surface. Dissociation constants (K d ) for specific binding were obtained via a single-site non-competitive binding model and are summarized in Fig. 4B . Consistently, A5-mβG exhibited lower K d values (0.6-1.1 nM) than A1-mβG (1.9-3.0 nM), but relatively strong binding of both fusion proteins was observed to Panc-1 and MCF-7 tumor cells and to HAAE-1 vascular endothelial cells grown to mimic the tumor vasculature.
To address the specificity of A1-mβG and A5-mβG, we preformed the above quantitative binding assay on confluent endothelial cells (HAAE-1), which behave like cells in the normal vasculature and do not express phosphatidylserine externally . No measurable specific binding was detected (Fig. S5, Supplementary Material) . Lack of any measurable binding to normal controls indicated that A1-mβG and A5-mβG preferentially bind to tumor-associated vasculature in addition to tumor cells.
Binding stability was determined in the presence Ca 2+ over 3 days, as shown in Fig. 4C . The MCF-7 and Panc-1 cell lines displayed excellent stability, with A1-mβG retaining significantly more bound protein than A5-mβG on Days 1 and 2 (P < 0.001), but detectable differences disappearing by Day 3. Contrastingly, HAAE-1 cells exhibited large initial drops in stability, with 20% still remaining on Day 3; however, bound protein was not significantly different for A1-mβG vs. A5-mβG on any day.
A5-mβG combined with SN-38G is as effective as SN-38
We simulated EPT in vitro to establish the efficacy of A1/A5-mβG combined with the prodrug SN-38G against human pancreatic (Panc-1) and breast (MCF-7) cancer cell lines along with non-confluent endothelial cells (HAAE-1), which mimic the tumor vasculature. Dose-response curves were determined for A5-mβG + SN-38G, with SN-38G and SN-38 alone as controls, on Day 6 of treatment (Fig. 5) . Treatment with A5-mβG or A1-mβG without prodrug did not lead to any significant changes in viability on any day (Fig. S6, Supplementary Material) . A5-mβG + SN-38 was statistically indistinguishable from the SN-38 drug control for both Panc-1 (Fig. 5A ) and HAAE-1 cell lines (Fig. 5C ) at and beyond Day 4 (Fig. S6 , Supplementary Material) for all concentrations of drug/prodrug. A5-mβG + SN-38G was as effective as SN-38 on MCF-7 cells on Day 6 at concentrations ≤100 nM (Fig. 5B ). Therapeutic indices (QIC 50 ) were 50.5 for Panc-1, 28.7 for MCF-7 and 2.1 for HAAE-1 cells. Full simulated EPT data sets for all days are given in Supplementary Material (Fig. S6) , including data for A1-mβG + SN-38-G (Fig. S6A, C) , which was excluded from Day 6 dose-response curves for clarity, as it was quickly deemed less effective than A5-mβG.
Discussion
Here, we presented pure forms of two novel annexin-βG fusion proteins that enable high-dose, site-specific combination chemotherapy. The A5-16a3 mutant βG construct emerged as the best candidate moving forward, matching SN-38 toxicity when combined with SN-38G. We also provided considerable evidence for the tumor-type independence of the annexin-directed EPT approach as A5/A1-mβG showed strong targeting and killing capabilities toward human cancer cell lines, strong binding and moderate killing toward endothelial cells grown to mimic the tumor vasculature, but no binding to normal endothelial cell controls. The production method presented is the first suspension-based approach published for βG fusion proteins; suspension-based production will play an important role in transitioning the βG platform toward clinical testing, as suspension cultures readily scale to bioreactors for large-scale production. Further, the production method presented is the first for βG fusion proteins that is chemically defined, completely devoid of serum within the production environment, an essential first step toward translational work. However, current yields still need to be improved before translation can be realized. Yields upwards of 10 mg/ml should be possible (Wurm, 2004) , but may require a multi-site genomic integration approach with clonal selection. Nevertheless, the βG fusion proteins presented here are the first to be successfully purified in a chemically defined production and serve as proof of concept.
The annexin-βG fusion constructs retained the essential features of their constituent proteins. A5-mβG binding matched previously reported K d values of A5 alone binding to cell surface phosphatidylserine, ranging from 0.1 to 2 nM (Schutters and Reutelingsperger, 2010; Neves et al., 2013) . As expected, A1-mβG exhibited higher K d values than A5-mβG. However, A1-mβG displayed lower K d values for cultured cells expressing phosphatidylserine than previously reported for A1 alone binding to immobilized lipid bilayers containing phosphatidylserine,~39 nM (Kastl et al., 2002) ; there are no previous reports of A1 dissociation constants for cultured cells. We have previously shown that annexin A5 fusion proteins will not bind to normal endothelial cell controls Krais et al., 2013) , and we here extend this finding to A1 fusion proteins by demonstrating that A1-mβG and A5-mβG bind only to cells expressing phosphatidylserine in a calcium-dependent manner with no detectable specific binding to normal controls lacking the phosphatidylserine target.
Cell-surface binding stability did not emerge as a significant factor to favor use of A1 vs. A5 for annexins in fusion. For the HAAE-1 cell line where A5-mβG and A1-mβG showed lower stability overall, bound protein retention did not differ for A1 vs. A5. For cell lines where both A5-mβG and A1-mβG exhibited remarkable stability, A1-mβG did show markedly higher stability initially; however, by Day 3 differences in bound protein were no longer significant. Differences in fusion protein binding stability between cell lines have been consistently observed ( Krais et al., 2013) and likely result from the high diversity of phosphatidylserine expression between cell lines of different cancer types (Riedl et al., 2011) and even between cell lines of the same cancer type (Chu et al., 2013) . The lack of evidence for enhanced stability of A1 fusions compared with A5 fusions, paired with the lower K d and higher activity seen in A5 fusions, strongly favors further investigation of the A5-mβG construct. A5 fusions utilizing similar linkers have been shown to localize efficiently to the tumor site while maintaining their binding and enzymatic capabilities, indicating sufficient serum stability (Van Rite et al., 2013) . Glycosylation on βG will further help to shield annexin-βG fusion proteins from proteolytic cleavage en route to the tumor site compared with previous work on non-glycosylated proteins (Zhong and Somers, 2012) .
Activity retention at a physiological pH is important for βG to be therapeutically relevant. Previously, Chen et al. (2011) showed that the βG mutant S2, which retains~15% activity, afforded significant in vivo tumor response whereas wild-type βG failed to create any effect (Chen et al., 2011) . Here, A5-mβG, with the 16a3 mutation, retained 28% specific activity at pH 7.4 compared with specific activity at pH 4.5, which matched previously reported activity retention values for the 16a3 βG mutation (Chen et al., 2012) . A1-mβG retained less specific activity than A5-mβG but still improved upon the 1-2% activity retention of reported for wild-type βG (Chen et al., 2008 (Chen et al., , 2012 .
The 16a3 βG mutation clearly enhances βG therapeutic relevance, and, importantly, the increased efficacy of the 16a3 mutation is sufficiently maintained in annexin-βG fusions, especially A5-mβG. Unexpectedly, A5-mβG also displayed higher specific activity at pH 4.5 than A1-mβG. We propose that this difference is due to posttranslational processing difficulties that arise due to the glycosylation site on A1, upstream of βG, which is not present on A5, as post-translational processing is essential for the establishment of βG enzymatic activity.
The annexin-βG fusion proteins produced here are the largest annexin fusion proteins engineered to date, measuring~30 nm in diameter. This significant size allows annexin-βG fusions to benefit from passive targeting via the enhanced permeability and retention effect, since this effect is generally present only for particles 20-300 nm in diameter. Active targeting for particles below 50 nm have been shown to further boost this effect, suggesting that annexin-βG fusions will experience enhanced targeting once translated in vivo (Torchilin, 2006) .
Promising designer prodrugs for βG are currently being developed, which will afford even greater potency to this EPT system. One such prodrug is a duocarmycin SA analog (Tietze et al., 2011) , which selectivity binds the N3 of adenine in AT rich-minor DNA groove regions. Duocarmycin SA is one of the strongest known anticancer compounds, but even analogs trigger severe myelotoxicity (Hurley et al., 1988; Puyo et al., 2014) . However, βG mediated prodrug to drug conversion within the tumor site could mitigate the side effects associated with systemic administration and may allow for the clinical use of duocarmycin SA analogs, alone, or in combination with other βG generated chemotherapeutics. Duocarmycin SA analog prodrugs have demonstrated remarkable efficacy against CL1-5 lung cancer xenografts via βG gene-directed EPT (Chen et al., 2013) and are capable of producing astounding therapeutic windows approaching 10 6 (Tietze et al., 2010) .
Conclusions
Annexin-βG fusion proteins allow for combination, on-site chemotherapy of FDA-approved drugs within the same enzyme platform, while enabling tumor type-independent targeting and promising to be non-immunogenic due to their human nature. The successful development of a chemically defined, fully scalable production method for pure βG fusion proteins brings βG-based EPT one step closer to realizing the ultimate goal of translation. The βG fusion protein A5-mβG emerged as a particularly promising, with excellent cellsurface binding capabilities and on par cytotoxicity with the matched drug, SN-38, when combined with the prodrug SN-38G. A5-mβG is also promising therapeutically, as it retained~30% specific activity at a pH of 7.4. Since previous reports have shown that only~15% activity retention is necessary to transfer significant therapeutic activity to wild-type βG, A5-mβG emerges as an excellent candidate for future translationally oriented work. Future work will aim to scale up the production of mA5-βG via a bioreactor and then investigate in vivo efficacy, where we expect that the A5 targeting system will perform with the same specificity displayed in Van Rite et al. (2013) but will afford more flexibility with respect to the types of drugs that can be generated with minimal risk of side effects. While many EPT approaches show promise, most cannot be readily translated due to immunogenicity or are confined to a single-agent approach. Importantly, βG opens up a new avenue for EPT-mediated combination chemotherapy, including FDAapproved drugs, within the same enzyme platform. This allows for high-dose, localized therapy to be specifically tailored to each patient. Furthermore, the βG fusion proteins are near fully human constructs, and thus, likely non-immunogenic, a significant improvement upon the non-human enzymes generally utilized for EPT. We thus conclude that the novel βG fusion proteins developed here, especially A5-mβG, significantly improve upon the current state of EPT.
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